Reuters logo
a month ago
BRIEF-Kamada to withdraw European Marketing Authorization application for inhaled ALPHA-1 antitrypsin
June 22, 2017 / 11:28 AM / a month ago

BRIEF-Kamada to withdraw European Marketing Authorization application for inhaled ALPHA-1 antitrypsin

1 Min Read

June 22 (Reuters) - Kamada Ltd

* Kamada announces withdrawal of European Marketing Authorization application for inhaled ALPHA-1 antitrypsin for treatment of ALPHA-1 antitrypsin deficiency disease

* Kamada Ltd -following discussions with EMA, Kamada concluded that EMA does not view data submitted to date as sufficient for approval of MAA

* Says Kamada intends to utilize data to be obtained from pivotal study to resubmit MAA to EMA

* Kamada - is currently in advanced discussions with U.S. FDA to secure approval of IND this year to conduct U.S. phase 3 pivotal study of inhaled AAT for treatment of AATD that would begin in 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below